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Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is a
disorder of adrenal steroid biosynthesis, leading to hypocortisolism, hypoaldosteronism,
and hyperandrogenism. Impaired quality of life (QoL) has been demonstrated in women
with CAH, but data on men with CAH are scarce. We hypothesized that disease severity
and poor treatment control are inversely associated with QoL. In this study, 109 men (16-
68 years) with 21OHD were included. The WHOQOL-BREF questionnaire was used to
measure self-reported QoL domain scores on a 0-100 scale, where higher scores reflect
better QoL. QoL domain scores were compared to published data on healthy and
chronically ill reference populations from France, Germany, the Netherlands, and the
United Kingdom. Differences in QoL scores among groups of disease severity and
treatment control were tested within the study population. Overall, the men with CAH in
this study appeared to rate their QoL as good. Median domain scores were 78.6 (IQR:
67.9-85.7) for physical health, 79.2 (IQR: 66.7-87.5) for psychological health, 75.0 (IQR:
58.3-83.3) for social relationships, and 81.3 (IQR: 71.9-90.6) for environment. In general,
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these scores were similar to WHOQOL-BREF domain scores in healthy references and
higher compared to chronically ill reference populations. The domain scores did not differ
among genotype groups, but patients with undertreatment or increased 17-
hydroxyprogestrone concentrations scored higher on several QoL domains (p<0.05).
Patients treated with dexamethasone or prednisone scored higher on the physical health,
psychological health, and social relationships domains, but not on the environmental
domain. In conclusion, QoL domain scores appeared to be comparable to healthy
reference populations and higher compared to patients with a chronic illness. QoL was
not influenced by genotype, but undertreatment and use of dexamethasone or
prednisone were associated with higher QoL.
Keywords: CYP21A2, WHOQOL BREF, quality of life, congenital adrenal hyperplasia (CAH), 21
hydroxylase deficiency
INTRODUCTION
Congenital adrenal hyperplasia (CAH) is an inherited, chronic
disorder of adrenal steroid biosynthesis. The most common
cause is a mutation in the CYP21A2 gene leading to 21-
hydroxylase deficiency (21OHD), which results in impaired
production of cortisol and increased production of adrenal
androgens, leading to virilization of the external genitalia in 46,
XX individuals (1). Aldosterone production is also impaired to a
variable degree, depending on the severity of the enzyme
deficiency (1, 2).
Treatment consists of glucocorticoid substitution and, if
necessary, substitution of mineralocorticoids as well (1). By
treatment with glucocorticoids, the negative feedback on the
pituitary gland is restored, leading to a decrease in adrenal
androgen production. Mostly, however, supraphysiological
dosages of glucocorticoids are necessary to decrease adrenal
androgen production sufficiently. Therefore, balancing medical
treatment between under- and overtreatment is important to
prevent long-term consequences of chronic androgen exposure
and chronic supraphysiological glucocorticoid exposure.
Common long-term complications due to insufficient adrenal
androgen suppression and insufficient glucocorticoid
supplementation are disturbed pubertal development, reduced
final height, decreased reproductive function, including testicular
adrenal rest tumor development, and adrenal crises. Long-term
complications due to chronic supraphysiological glucocorticoid
exposure include decreased bone mineral density, increased risk
of obesity, and cardiovascular morbidity (3–5).
In patients with CAH, several factors may affect quality of life
(QoL), such as the development of long-term complications, the
use of medication, and poor treatment control (6–8). Impaired
QoL has been reported in patients with CAH, mostly in women
[reviewed by Reisch et al. (3)]. Data on QoL in men with CAH
are scarce, although separate analysis of QoL in male and female
patients is important since clinical presentation and
complications vary greatly between the two sexes. Results are
contradictory with some papers describing impaired QoL (6, 9,
10), and others equal (11) or better (12) QoL in men with CAH
compared to a control population [recently reviewed by Daae
et al. (13)].
The dsd-LIFE study provides an opportunity to fill this
knowledge gap by studying a large European multicenter
cohort of men with CAH in which we assessed QoL using the
WHOQOL-BREF questionnaire. We hypothesized that QoL
would be impaired in men with CAH compared to healthy
control populations, and that genotype, medication regimen,
and treatment control would be associated with QoL.
METHODS
Patients
Adult men with CAH were included from the dsd-LIFE study, a
cross-sectional clinical outcome study of individuals with
disorders/differences in sex development (DSD). The
methodological background of the dsd-LIFE study is described
in more detail elsewhere (14). Fourteen study centers in six
European countries (France (n=4), Germany (n=4), Poland
(n=2), the Netherlands (n=2), Sweden (n=1), and the United
Kingdom (UK) (n=1)) included participants with DSD (n=1040)
from February 2014 until September 2015. In addition, male
patients with CAH (karyotype 46,XY) were invited to participate
in the dsd-LIFE study as they may face similar challenges as DSD
patients, even though they are not classified as such. In total, 121
men with CAH (karyotype 46,XY), aged 16 - 68 years, were
included. Written informed consent was obtained from all
participants. The study was approved by the medical ethics
committee at the Charité Universitätsmedizin Berlin (reference
number EA2/069/13) and the local ethics committees of the
other study centers as appropriate for each country.
Patients were investigated at their local medical center and
treated according to the Endocrine Society guidelines (1). All
patients underwent medical examination and filled out several
Abbreviations: 17OHP, 17-hydroxyprogesterone; 21OHD, 21-hydroxylase
deficiency; BMI, Body mass index; CAH, Congenital adrenal hyperplasia; DSD,
Disorders/differences in sex development; GBB-24, Giessen Subjective Complaints
List; HADS, Hospital Anxiety and Depression Scale; IQR, Interquartile Range; SF-
36, Short form 36; UK, United Kingdom; QoL, Quality of life; WHOQOL-BREF,
World health organization quality of life questionnaire, short version.
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questionnaires, including the WHOQOL-BREF (15). Additional
data were retrieved from medical records. General patient
characteristics and clinical parameters included: country of
inclusion, height, weight, BMI, age, age at diagnosis, CYP21A2
genotype, medication use, subjective treatment control,
satisfaction with care in childhood, smoking behavior, work,
leisure time activities, sports, and educational level. The variable
age was dichotomized into <30 years and ≥30 as described in
other studies (9, 11). The patients were classified into genotype
groups null (0), A, B, and C, based on the residual enzymatic
activity (16). Enzyme activity is lowest in genotype 0 (0%
remaining activity), with increasing activity from A through C
(17). Therefore, patients with genotype group 0 are most severely
affected, while genotype groups A, B, and C have decreasing
severity. The patients’ educational levels were established
according to the EU classification as low, medium, and high (18).
Reference Populations
As matched control groups were not available in the dsd-LIFE
study, this study used control groups from the literature. QoL data
on female patients with CAH were derived from an earlier DSD-
LIFE study onQoL in patients with DSD (19). This study included a
sample of 226 female patients with CAH from France, Germany,
the Netherlands, Sweden and the UK. In addition, healthy as well as
chronically ill populations from France (20), Germany (21), the
Netherlands (22), and the UK (23) were used for comparison.
Reference populations from the Netherlands and the UK contained
bothmen andwomen, while France and Germany reported gender-
specific QoL scores. For France, data of self-reported healthy
(n=5167) and chronically ill (n=1638) adult men, of which 656
were young adults (18-24 years) and 897 were elderly people (65-75
years), were derived from the National Health Barometer 2005, a
periodic study by the French National Institute for Preventive and
Health Education (20). For Germany, data of 925 men from a
representative urban sample of the adult general population were
available, including 124 young adults (18 to 25 years) and 155
elderly people (≥66 years). Additionally, 261 men and women from
this representative urban sample reporting a physical chronic
disease were used as a chronically ill reference population (21).
For the Netherlands, data from a healthy control group were used,
matched for age and sex ratio (mean age 34.8 years) to a sample of
patients with a mental chronic disease. The matched control group
was taken from a pooled data set based on Dutch general
population studies (1999–2002) (22). For the UK, a study
including healthy and non-healthy people from all over the UK
was available. The healthy people included students and student
nurses. The age range for the entire cohort was 16–105 years with a
mean age of 45 years; 64% of the study participants were
women (23).
WHOQOL-BREF
To assess QoL, the WHOQOL-BREF questionnaire was used
according to guidelines provided by the World Health
Organization (15). The WHOQOL-BREF is a shortened
version of the WHOQOL-100, consisting of 24 questions
concerning QoL on four different domains: physical health,
psychological health, social relationships, and environment.
Questions are rated on a 5-point Likert scale and domain
scores represent the mean score of the items within each
domain. The scores are multiplied by four, resulting in scores
ranging from 4 to 20, to be directly comparable with scores
derived from the WHOQOL-100. These scores can then be
converted to a 0-100 scale, with high scores reflecting good QoL.
Treatment Control
Treatment accuracy was estimated by the treating physicians in
subjective scores: undertreatment, accurate treatment, or
overtreatment. Blood hormone concentrations were also used
to indicate treatment accuracy as high concentrations of
androstenedione and 17-hydroxyprogesterone (17OHP)
indicate inadequate adrenal androgen suppression. Therefore,
blood samples were obtained at study inclusion. Samples were
mostly taken in the morning, before intake of the glucocorticoid
medication (14). Androstenedione and 17OHP concentrations
were measured in the local hospital laboratory and compared to
local reference values. The results were reported as “below
reference range”, “within reference range”, “above reference
range up to twice the upper limit”, and “more than twice the
upper limit of the reference range”. To increase the number of
patients per category, we combined the latter two categories into
the category ‘above reference range’.
Statistical Analysis
SPSS Statistics 25 (SPSS Inc., Chicago, IL, USA) was used for all
analyses. First, descriptive analyses were performed for each
variable. After checking missing data and the distributions of
the continuous background variables and QoL scores for
normality, median and interquartile ranges (IQR = Q1-Q3) were
calculated. The overall and country-specific median QoL scores
for all 4 domains were compared to the reference populations
described above without further statistical analyses. Following, the
QoL domain scores (physical, psychological, social relationships,
and environment) were compared between male CAH patients
with different ages, educational levels, and treatment regiments
using the Mann-Whitney-U test. For BMI and glucocorticoid
treatment dosages related to the QoL domain scores, Spearman
correlation coefficients were calculated. Overall differences in QoL
domain scores among CAH patients with different genotypes and
various glucocorticoid treatment groups were assessed with the
Kruskal-Wallis test or the Jonckheere-Terpstra test, and post-hoc
Mann-Whitney-U tests were applied if the p-value was ≤0.15. In
general, p-values <0.05 were considered statistically significant, but
due to multiple testing the p-values from the latter analyses should
be interpreted with caution.
RESULTS
Quality of Life in Patients With Congenital
Adrenal Hyperplasia
After exclusion of 10 men with CAH who did not complete the
WHOQOL-BREF and two men with an 11ß-hydroxylase
deficiency, 109 men with CAH due to 21-hydroxylase
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deficiency were included in this study on QoL. General
characteristics are shown in Table 1.
QoL Domain Scores in Patients With CAH
Overall, the men with CAH rated their QoL as good with median
domain scores of 78.6 (IQR: 67.9–85.7), 79.2 (IQR: 66.7–87.5), 75.0
(IQR: 58.3–83.3), and 81.3 (IQR: 71.9–90.6) for physical health,
psychological health, social relationships, and environment,
respectively (Table 2). The country-specific median scores
appeared to be lowest on all domains in patients from the UK
and highest in Dutch patients (Table 2). Men <30 years scored
higher (median score 75.0, IQR 60.4 – 91.7) on the social
relationships domain compared to men ≥30 years (median score
66.7, IQR 50.0 – 83.3, p=0.03). For the domains physical health and
psychological health, a few not statistically significant differences
were seen between educational levels (Supplement A). No
statistically significant correlation coefficients were found between
the QoL domain scores and BMI and treatment dosages, except for
the environmental domain and BMI (r=-0.26, p=0.006).
Quality of Life Domain Scores Among Different
Genotypes
The QoL domain scores differed only slightly among the different
genotype groups, and no statistically significant differences were
observed (Supplement B). Interestingly, the median QoL
domain scores seemed among the highest for all four domains
in men with genotype 0, who are affected most severely.
Quality of Life Domain Scores for Medication Use
and Treatment Control
Figures 1A-D show the results for the QoL domain scores
stratified by glucocorticoid treatment group. No statistically
significant differences were seen in the environmental domain
scores (Kruskal-Wallis p=0.41), but the p-values from the
Kruskal-Wallis tests pointed towards differences among the
treatment groups in the physical health (p=0.08), psychological
health (p=0.05), and social relationships (p=0.03) domains.
Patients treated with prednisone and dexamethasone had the
highest scores in these domains. The largest differences were
observed between dexamethasone and >1 glucocorticoid
treatment in the physical health and social relationships
domains and between prednisone and prednisolone treatment
in the psychological health domain. Patients who were treated
with fludrocortisone had lower QoL scores on the physical health
domain (n=79, median: 78.6, IQR: 64.3-85.7) compared to
patients who did not receive fludrocortisone (n=30, median:
82.1, IQR: 74.1-92.9; p=0.03). Subjective treatment accuracy did
not seem to influence the QoL scores greatly (Table 3). However,
undertreated patients had higher domain scores on the social
relationships and environmental domains compared to patients
who were accurately treated (p=0.04 and p=0.01, respectively).
Patients with 17OHP concentrations above the reference range,
indicating inadequate adrenal suppression, reported higher
domain scores on the psychological health domain compared
to patients with 17OHP concentrations within reference range
(p=0.01) (Table 3).
Quality of Life in Patients With Congenital
Adrenal Hyperplasia Compared With
Reference Populations
QoL Domain Scores in Male Patients With CAH
Compared to Female Patients With CAH
QoL domain scores appeared to be higher in male patients with
CAH compared to female patients with CAH on all four domains
(Table 2).
Quality of Life Domain Scores in Patients With
Congenital Adrenal Hyperplasia Compared With
Healthy Reference Populations
The physical health domain scores appeared to be similar in the
total cohort of men with CAH compared to healthy subjects
from France, Germany, and the UK. In country-specific scores,
patients with CAH from France and the UK scored lower than
their respective reference populations, whereas this was reverse
for the Dutch CAH patients. (Table 2).
TABLE 1 | General characteristics of 109 men with CAH.
Variable N Result Median (IQR) or
Number (%)
Age (years) 109 29.0 (21.0–40.8)










Height (cm) 108 170.0 (166.3–175.0)
BMI (kg/m2) 108 25.4 (22.6–29.8)








































Continuous variables are displayed as median (IQR: Q1–Q3). Categorical variables are
displayed as number of participants with percentage. Patients were classified according to
severity of the disease into genotype groups null (0) through group C (17).
21OHD, 21-hydroxylase deficiency; BMI, body mass index; IQR, interquartile range.
*Six patients used hydrocortisone and dexamethasone, and one patient used
hydrocortisone and prednisolone. **Hydrocortisone equivalent scores were calculated
for the total dose of glucocorticoids used per day (24).
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On the psychological health domain, the total group of men
with CAH appeared to have a similar score as the healthy
reference population from Germany, but a higher QoL score
compared to healthy references from France, the Netherlands,
and the UK (Table 2). Men with CAH from France and the
Netherlands appeared to have rated their psychological health
higher than the corresponding healthy reference populations,
whereas men with CAH from the UK seemed to score lower than
the corresponding healthy reference population.
For the social relationships domain, the score of the cohort of
men with CAH appeared to be similar to the scores of healthy
subjects from all reference populations. The country-specific
scores were much higher and lower for CAH patients than for
healthy references in the Netherlands and the UK, respectively.
On the environmental domain, the total cohort of men with
CAH appeared to report higher scores compared to healthy
reference populations from Germany, the Netherlands, and the
UK, with CAH patients fromGermany and the Netherlands rating
their QoL much higher compared to the corresponding healthy
reference populations. Men with CAH from the UK seemed to
have similar scores as the healthy UK reference population.
QoL Domain Scores in Patients With CAH Compared
to Chronically Ill Reference Populations
In comparison to chronically ill reference populations from
France, Germany, and the UK (the latter comprising patients
with diabetes only), higher scores were reported in the total
cohort of men with CAH and in the country-specific cohorts for
France, Germany, the Netherlands, and Sweden in all but one
domain. In the social relationships domain, CAH patients from
France, Sweden, and the UK seemed to score lower than most
chronically ill reference populations. Men with CAH from the
UK appeared to have lower median scores compared to the
corresponding chronically ill reference population in
all domains.
DISCUSSION
This is the first international multicenter study examining QoL
using the WHOQOL-BREF questionnaire in a large cohort of
adult male patients with CAH. This study shows that men with
CAH rate their QoL as good. The overall scores appeared to be
similar to scores obtained with the WHOQOL-BREF
questionnaire in healthy reference populations from France
(20), Germany (21), and the UK (23), and higher compared to
a healthy reference population from the Netherlands (22). We
also presented data on chronically ill reference populations, as
having a chronic disease may affect expectations of life, leading to
higher QoL scores due to overrating (25). The data showed that
men with CAH in general appeared to rate their QoL higher
compared to female patients with CAH and patients with other
chronic diseases.
Although men with CAH may face different complications of
their chronic disease and often require lifelong therapy, they do
not seem to report a worse QoL on the physical and
psychological health domains compared to healthy or
chronically ill references. CAH patients from the UK form an
exception, which is in line with an earlier study of Arlt et al. who
found that only a minority of CAH patients in the UK receive
optimal specialist endocrine care (6). The findings suggest that
psychological wellbeing does not seem to be largely affected in
men with CAH, which is in contrast to previously reported
higher prevalence rates of psychiatric morbidity in men with
CAH (26). Patients with mental health issues, however, might be
less likely to participate in studies or fill out questionnaires on
QoL, and may be underrepresented in the dsd-LIFE database.
Social relationships as well as environmental QoL domain scores
appeared to be similar or higher in men with CAH compared to
reference scores, but several country-specific scores for social
relationships were lower. In contrast, higher QoL domain scores
were observed in patients with CAH < 30 years old compared to
TABLE 2 | QoL domain scores—men with CAH and country-specific healthy and chronically ill reference populations.
Physical health Psychological health Social relationships Environment
Total cohort Men with CAH n = 109 78.6 (67.9–85.7) 79.2 (66.7–87.5) 75.0 (58.3–83.3) 81.3 (71.9–90.6)
DSD-LIFE (19) Women with CAH n = 211 68.1 ± 18.9 65.6 ± 18.4 64.8 ± 20.5 74.1 ± 15.7
France
(20)
CAH n = 30 71.4 (63.4–78.6) 77.1 (66.7–87.5) 66.7 (50.0–75.0) 76.6 (71.1–82.0)
Healthy n = 5,157 81.6 ± 0.2# 69.5 ± 0.2# 75.6 ± 0.2# -
ill n = 1,638 68.4 ± 0.4# 67.5 ± 0.3# 71.8 ± 0.4# -
Germany
(21)
CAH n = 46 83.9 (75.0–92.9) 79.2 (70.8–87.5) 75.0 (58.3–83.3) 84.4 (75.0–90.6)
Healthy* n = 925 78.8 ± 16.9 75.9 ± 14.7 72.3 ± 18.2 71.2 ± 14.3
ill^ n = 261 53.4 ± 20.3 62.7 ± 16.3 68.0 ± 16.9 67.2 ± 13.4
Netherlands
(22)
CAH n = 12 89.3 (66.1–96.4) 81.3 (59.4–91.7) 87.5 (68.8–100.0) 89.1 (67.2–96.9)
Healthy^ n = 218 70.1 ± 11.9 64.8 ± 9.0 71.3 ± 13.4 74.0 ± 9.3
Sweden CAH n = 9 82.1 (67.9–85.7) 79.2 (66.7–81.3) 66.7 (50.0–79.2) 81.3 68.8–93.8)
United Kingdom
(23)
CAH n = 12 58.9 (45.5–85.7) 60.4 (32.3–72.9) 41.7 (10.4–75.0) 65.6 (52.3–78.1)
Healthy^ n = 1,328 76.5 ± 16.2 67.8 ± 15.6 70.5 ± 20.7 68.2 ± 13.8
ill^ n = 524 67.8 ± 19.6 67.7 ± 16.1 70.1 ± 19.7 71.1 ± 15.5
Median WHOQOL-BREF domain scores and interquartile range (Q1–Q3) for the overall cohort and from country-specific analysis were calculated. These scores were compared to mean
domain scores plus standard deviation (SD) or standard error of the mean (SEM) of a cohort of female patients with CAH from the literature (19) and to country-specific reference
populations from the literature (20–23). If available, both healthy and chronically ill reference populations were used. Chronically ill reference populations comprised patients with a chronic
physical illness; in the United Kingdom, only patients with a chronic endocrine disorder were included. Bold, Subgroups of men with CAH.
#Standard error of the mean instead of standard deviation.
*The German healthy reference population contained all male patients from the cohort including chronically ill patients.
^Quality of Life scores were obtained from a reference population containing both men and women.
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patients ≥ 30 years on the social relationships domain. This is
supported by Skevington et al., who report decreasing
WHOQOL-BREF domain scores with increasing age in a large
healthy international cohort (27).
In country-specific comparisons, we observed high scores on all
four domains in the Dutch men with CAH compared to men with
CAH from other countries, along with scores of German and
Swedish patients on some domains. These results are not reflected
in the reference literature, as the Dutch healthy reference population
had the lowest scores on the physical and psychological health
domains compared to reference populations from the other
countries and similar scores on the other domains (20–23).
Possibly, the Dutch reference study does not accurately reflect the
current Dutch general population, as the data were collected 15
years earlier than the dsd-LIFE study from a small sample. Another
notable finding was that UK patients with CAH reported low scores
on all four domains. Compared to healthy references from the UK
(23), men with CAH rated QoL rather comparable on the
environmental domain, but the scores on the other domains
seemed much lower. However, the healthy reference population
from the UK consisted of both male and female university students
and student nurses, most likely resulting in a young and highly
educated cohort. This may have led to overestimation of the QoL
scores for the UK general population.
A few other studies reported QoL in men with CAH, but these
used different questionnaires (13). Our results indicate a good
A B
DC
FIGURE 1 | Quality of Life domain scores of men with CAH divided by glucocorticoid type. WHOQOL-BREF scores in different glucocorticoid type groups were
calculated for four different domains: (A) physical health, (B) psychological health, (C) social relationships, and (D) environment. WHOQOL-BREF scores were converted
to a 0–100 scale where higher scores reflect better QoL. Boxes represent median and 25th–75th percentiles, while whiskers show minimum–maximum domain scores.
Differences among the groups were assessed using the Kruskal–Wallis test (p-value mentioned above the graph). When applicable, the Mann–Whitney-U test was used
to provide some insight into the main differences between groups (p-values above bars; only p-values ≤ 0.05 are shown, but should be interpreted with caution due to
the number of tests performed).
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QoL in men with CAH, which corresponds to the results found
by Falhammar et al. (11), although impaired QoL has also been
reported (6, 9, 10). Strikingly, Reisch et al. showed impaired QoL
in 36 men with CAH on the GBB-24, whereas QoL measured
with the HADS and SF-36 did not differ from a healthy reference
population (10). This stresses the importance of using similar
questionnaires to assess QoL in patients with CAH to make
comparison among different study populations possible.
The QoL in men with CAH in our study was also higher
compared to patients with primary adrenal insufficiency,
although QoL in the latter study was not measured by
WHOQOL-BREF (10). Furthermore, QoL measured by
WHOQOL-BREF in men with CAH was higher compared to
patients with DSD, including Turner Syndrome, Klinefelter
syndrome, XY female DSD, and XY male DSD, as described in
another study of dsd-LIFE (19). One of the differences between
these diseases is the presence of increased adrenal steroid
precursors in CAH, in contrast to patients with primary
adrenal insufficiency or other forms of DSD. Previously, we
showed that several adrenal steroid precursors that are elevated
especially in CAH patients with poor hormonal control are able
to activate the glucocorticoid receptor, which might explain why
patients with CAH experience fewer complications of their
cortisol deficiency than expected (28), possibly leading to
better QoL. Furthermore, most males with CAH do not report
complaints from testosterone deficiency as they have sufficient
androgens from adrenal origin. Our observations argue in favor
of the common treatment strategy of a more individualized
treatment approach. In patients with CAH who want to
achieve good fertility, adrenal androgen levels should be within
the normal reference range, even when supraphysiological
dosages of glucocorticoids are necessary. In older patients, in
whom fertility issues are no longer relevant, more physiological
dosages of glucocorticoids could be used to prevent long-term
complications of glucocorticoid treatment.
The QoL observed in men with CAH in this study was also
higher compared to the QoL observed in women with CAH, as
described in another study of dsd-LIFE (19). This may reflect the
differences in clinical presentation and complications, as female
patients have more problems due to increased adrenal androgens,
such as virilization andmasculinization, which consequently require
corrective surgery and may affect QoL negatively.
The QoL domain scores did not differ among the different
genotypes, confirming the findings in a previous study (11).
However, we did find that fludrocortisone therapy, given to the
most severely affected CAH patients, was associated with lower QoL
scores on the physical domain. Remarkably, men with genotype 0,
who are most severely affected, had relatively high median QoL
scores (Supplement B). Possibly, altered expectations of life are
more pronounced in this group of patients, who received their
diagnosis directly postnatally. Alternatively, one may speculate that
an early start of follow-up may have led to improved QoL, which is
in line with studies showing that a late diagnosis impairs QoL in
male CAH patients (11) and that neonatal screening for CAH
improves fertility in men with CAH (29).
Patients on dexamethasone or prednisone seemed to rate their
QoL on the physical health, psychological health, and social
relationships domains higher compared to patients that used
other types of glucocorticoids, but no differences were observed
on the environmental domain. This is in accordance with the
finding of Falhammar et al. (11). In contrast, Han et al. reported
lower QoL in patients using dexamethasone (30). However, the
latter patients could have been on any regimen including
dexamethasone mono-therapy as well as multiple glucocorticoids,
which may have influenced the QoL scores negatively. In addition,
our dexamethasone group contained only seven men, which might
have skewed the results positively. Men with CAH using multiple
glucocorticoids scored among the lowest on the physical health and
social relationships domains. Possibly, patients with poor hormonal
control are more likely to be treated with more than one
glucocorticoid eventually. We observed higher scores among
patients who were undertreated according to the subjective rating
of the treating physician, as well as among patients with increased
17OHP concentrations compared to patients with normal 17OHP
concentrations, but we did not find an association with
androstenedione concentrations. Falhammar et al. also reported
better QoL (PGWB questionnaire) in men with CAH in
undertreated compared to overtreated patients (11). We
hypothesize that male patients with CAH suffer less from androgen
excess due to undertreatment than from glucocorticoid excess in
TABLE 3 | QoL domain scores—subgroups based on subjective and objective treatment accuracy in men with CAH.




























































Median WHOQOL-BREF domain scores and interquartile range (Q1–Q3) for the subgroups based on subjective and objective treatment accuracy were calculated. 17-OHP, 17-
hydroxyprogesterone. Subjective treatment accuracy groups were compared using the Jonckheere–Terpstra test for trend, while 17-OHP concentration subgroups were compared using
the Mann–Whitney-U test. Bold: p < 0.05.
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overtreatment. Furthermore, elevated precursor steroids, such as
17OHP which also have glucocorticoid activity, may partially
compensate glucocorticoid deficiency in this patient group (31).
However, this potential association between treatment control and
QoL should be re-evaluated in future studies, as the subjective rating
of treatment control used in this cohort contains heterogeneity
among treating physicians, normal 17OHP levels do not reflect
accurate treatment, and an association with androstenedione
concentrations was absent.
Although we were able to include a large cohort of adult male
patients with CAH, our study design was mainly based on
descriptive analyses and did not include a reference population.
Therefore, we compared our domain scores with scores reported in
the literature, although only mean domain scores were available and
the German and France cohorts only reported gender-specific QoL
scores. This complicated the comparisons with our median domain
scores as no statistical analyses were possible. In addition, no data
on educational level of the reference populations were available.
Although all male patients with CAH were invited to participate in
some centers, it is likely that some declined because they do not
identify with DSD patient characteristics. Furthermore, all centers
involved in the dsd-LIFE study are tertiary care centers. Both of
these factors may have led to selection of the patient group towards
including more severely affected patients. However, this
substantiates our findings of good QoL in patients with CAH
even more. In contrast, selection of highly motivated patients may
have occurred, leading to overestimation of QoL. Until now, no cut-
off values for ‘good QoL’ have been described in the literature for the
WHOQOL-BREF.
CONCLUSIONS
In conclusion, adult male patients with CAH, who were treated
according to the international guidelines, rated their QoL as good
in this study. Most of their QoL domain scores appeared to be
comparable to healthy reference populations and higher
compared to female patients with CAH and patients with
other chronic illnesses. QoL was not influenced by genotype,
but undertreatment and use of dexamethasone or prednisone
were associated with higher QoL. Further studies are necessary to
investigate factors that may influence QoL in CAH patients in
more detail.
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